Platelets and stroke

Vascular Medicine

Volumn 4, Issue 3, 1999, Pages 165-172

  Smith, Nicholas M ^a   Pathansali, Rohan ^a   Bath, Philip M W ^a,b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Antiplatelet agents; Megakaryocytes; Platelets; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CELL ADHESION MOLECULE; CLOPIDOGREL; DIPYRIDAMOLE; THROMBOXANE; TICLOPIDINE;

DRUG MECHANISM; HEMOSTASIS; HUMAN; MEGAKARYOCYTE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTOPOIESIS;

EID: 0032885511     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358836x9900400307     Document Type: Review

References (72)

1. A2 polymorphism of platelet glycoprotein IIIa and risk of cardiovascular disease [letter]. Lancet 1997; 349: 1099.
2. Bath PMW, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996; 7: 157-61.
3. Thompson CB, Love DG, Quinn PG, Valeri CR. Platelet size does not correlate with platelet age. Blood 1983; 62: 487-97.
4. Bentfield-Barker ME, Bainton DF. Identification of primary lysosomes in human megakaryocytes and platelets. Blood 1982; 59: 472-81.
5. Chernoff A, Levine RF, Goodman DS. Origin of platelet derived growth factor in megakaryocytes in guinea pigs. J Clin Invest 1980; 65: 926-30.
6. Gladwin AM, Carrier MJ, Beesley JE, Lelchuk R, Hancock V, Martin JF. Identification of mRNA for PDGF b-chain in human megakaryocytes isolated using a novel immunomagnetic separation method. Br J Haematol 1990; 76: 333-39.
7. Rabellino EM, Levene RB, Lueng LK, Nachman RL. Human megakaryocytes II: expression of platelet proteins in early marrow megakaryocytes. J Exp Med 1981; 54: 88-100.
8. Gladwin A-M, Martin JF. The control of megakaryocyte ploidy and platelet production: biology and pathology. Int J Cell Clon 1990; 8: 291-98.
9. Martin JF, Slater DN, Trowbridge EA. Platelet production in the lungs. In: Schmitz-Schumann M, Menz G, Page JF (eds). PAF platelets and asthma. Basel: Birkhauser, 1987: 35-37.
10. Martin JF, Bath PMW. Platelets and megakaryocytes in vascular disease. In: Herman AG (eds). Antithrombotics: pathophysiological rationale for pharmacological interventions. Dordrecht: Kluwer Academic Publishers, 1991: 49-62.
11. Trowbridge EA, Warren CW, Martin JF. Platelet volume heterogeneity in acute thrombocytopenia. Clin Phys Physiol Meas 1986; 7: 203-10.
12. Corash L, Chen HY, Levin J et al. Regulation of thrombopoiesis; effects of degree of thrombocytopenia on megakaryocyte ploidy and platelet volume. Blood 1987; 70:177-85.
13. Martin JF, Trowbridge EA, Salmon GL, Slater DN. The relationship between platelet and megakaryocyte volumes. Thomb Res 1982; 28: 447-59.
14. Metcalf B, Warren CW, Slater DN, Trowbridge EA, Martin JF, Barer GR. Changes in megakaryocytes and platelets in simulated high altitude rats. Clin Sri 1984; 67 (suppl 9): 76a.
15. Harris RA, Peningyon DG. The effects of low dose vincristine on megakaryocyte colony forming cells and megakaryocyte ploidy. Br J Haematol 1984; 57: 37-48.
16. Martin JF. The relationship between platelet and megakaryocyte volumes. Blood Cells 1989; 15: 108-17.
17. Wu KK. Platelet activation mechanisms and markers in arterial thrombosis. J Intern Med 1996; 239: 17-34.
18. O'Brien JR, Etherington MD. 'Rebleeding' the reversal of shear stress activation of platelets - a possible clue to thrombogenesis. Thromb Res 1992; 65: 821-22.
19. Blann AD, Lip GYH, Islim IF, Beevers DG. Evidence of platelet activation in hypertension. J Hum Hypertens 1997; 11: 607-609.
20. Davi G, Gresele P, Violi F et al. Diabetes mellitus, hypercholesterolcmia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo; evidence derived from the study of peripheral arterial disease. Circulation 1997; 96: 69-75.
21. Brown AS, Hong Y, de Belder A et al. Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 802-807.
22. Gleerup G, Winther K. Smoking further increases platelet activity in patients with mild hypertension. Eur J Clin Invest 1996; 26: 49-52.
23. Bath PMW, Gladwin AM, Carden N, Martin JF. Megakaryocyte DNA content is increased in patients with coronary artery atherosclerosis. Cardiovasc Res 1994; 28: 1348-52.
24. Trowhridge EA, Slater DN, Kishk YT et al. Platelet production in myocardial infarction and sudden cardiac death. Thromb Haemost 1991; 52: 167-71.
25. Martin JF, Bath PMW, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991; 338: 1409-11.
26. D'Erasmo E, Aliberti G. Celi FS, Romagnoli E, Vecci E, Mazzuoli GF. Platelet count, mean platelet volume and their relation to prognosis in cerebral infarction. J Intern Med 1990; 227: 11-14.
27. Tohgi H, Suzuki H, Tamura K, Kimura B. Platelet volume, aggregation, and adenosine triphosphate release in cerebral thrombosis. Stroke 1991; 22: 17-21.
28. O'Malley T, Langhorne P, Elton RA, Stewart C. Platelet size in stroke patients. Stroke 1995; 26: 995-99.
29. Butterworth RJ, Bath PMW. The relationship between mean platelet volume, stroke subtype and clinical outcome. Platelets 1998; 9: 359-64.
30. D'Erasmo E, Acca M, Celi FS, Medici F, Palmerini T, Pisani D. Plasma fibrinogen and platelet count in stroke. J Med 1993; 24: 185-91.
31. D'Erasmo E, Aliberti G, Vecci E, Celi FS, Mazzuoli GF. Evaluation of platelet changes in completed stroke. Ital J Neurol Sci 1988; 9: 573-76.
32. Uchiyama S, Takeuchi M, Osawa M et al. Platelet function tests in thrombotic cerebrovascular disorders. Stroke 1983; 14: 511-17.
33. Gazzaniga PP, Ferroni P, Mina C, Pulcinelli FM. Rizzo PA. A multiparametric index of platelet in vitro aggregation in cerebrovascular disease. Ital J Neurol Sci 1987; 8: 561-66.
34. Galante A, Pietroiusti A, Silvestrini M, Stanzione P, Domenici B, Bernardi G. Leukocyte and platelet aggregation in patients with ischemic stroke: a case-control study. Eur Neurol 1993; 33: 442-45.
35. Uchiyama S, Yamazaki M, Maruyama S et al. Shear-induced platelet aggregation in cerebral ischemia. Stroke 1994; 25: 1547-51.
36. Lui L, Lin Z, Zheshuang S, Guangsen Z, Shenyong L, Ping C. Platelet hyperfunction exists in both acute non-haemorrhagic and haemorrhagic stroke. Thromb Res 1994; 75: 485-90.
37. D'Andrea G, Cananzi AR, Perini F et al. Platelet function in acute ischaemic stroke: relevance of granule secretion. Cerebrovasc Dis 1994; 4: 163-69.
38. Joseph R. D'Andrea G, Oster SB, Welch KMA. Whole blood platelet function in acute ischemic stroke. Stroke 1989; 20: 38-44.
39. Gaur SP, Garg RK, Agarwal S, Kar AM, Srimal RC. Platelet functions and lipid profile within 24 hours following an attack of T1A, thrombotic and haemorrhagic stroke. Indian J Med Res 1994; 99: 259-63.
40. Grau AJ, Sigmund R, Hacke W. Modilication of platelet aggregation by leukocytes in ischemic stroke. Stroke 1994; 25: 2149-52.
41. 2 in cerebral ischemia. Stroke 1985; 16: 10-14.
42. 2: a reliable indicator of platelet hyperfunction in patients with ischemic stroke. Acta Neurol Scand 1991; 83: 99-102.
43. Koudstaal PJ, Ciabattoni G, van Gijn J et al. Increased thromboxane biosynthesis in patients with cerebral ischemia. Stroke 1993; 24: 219-23.
44. Taomoto K, Asada M, Kanazawa Y, Matsumoto S. Usefulness of the measurement of plasma β-thromboglobulin (β-TG) in cerebrovascular disease. Stroke 1983; 4: 518-24.
45. Levine PH, Fisher M, Fullerton AL, Duffy CP, Hoogasian JJ. Human platelet factor 4: preparation from outdated platelet concentrates and application in cerebral vascular disease. Am J Hematol 1981; 10: 375-85.
46. Smith N, Blann A, Butterworth R, Bath P. von Willebrand factor, P-selectin and fibrinogen in acute stroke. Eur J Clin Invest 1997; 27 (suppl 1): 119 [abstract].
47. Zeller JA, Kessler C. Flow cytometric detection of platelet activation in patients with cerebral ischemia. Cerebromsc Dis 1997; 7 (suppl 4): 58.
48. Mulley GP, Heptinstall S, Taylor PM, Mitchell JRA. ADP-induced platelet release reaction in acute stroke. Thromb Haemost 1983; 50: 524-26.
49. Whitlock G, MacMahon S, Anderson C, Neal B, Rodgers A, Chalmers J. Blood pressure lowering for the prevention of cognitive decline in patients with cerebrovascular disease. PROGRESS Management Committee. Perindopril Protection Against Recurrent Stroke Study. Clin Exp Hypertens 1997; 19: 843-55.
50. Van Kooten F, Ciabattoni G, Patrono C, Schmitz PIM, van Gijn J, Koudstaal J. Evidence for episodic platelet activation in acute ischemic stroke. Stroke 1994; 25: 278-81.
51. Blann AD, Lip GYH, Beevers DG et al. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost 1997; 77: 1077-80.
52. Fijnheer R, Frijns CJM, Korteweg J et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997; 77: 1081-85.
53. Shah AB, Beamer N, Coull BM. Enhanced in vivo platelet activation in subtypes of ischemic stroke. Stroke 1985; 16: 643-17.
54. Woo E, Huang CY, Chan V, Chan YW, Yu LY, Chan TK. Beta-thromboglobulin in cerebral infarction. J Neurol Neurosurg Psychiatry 1988; 51: 557-62.
55. Iwamoto T, Kubo H, Takasaki M. Platelet activation in the cerebral circulation in different types of ischemic stroke and Binswanger's disease. Stroke 1995; 26: 52-56.
56. The International Stroke Trial Collaborative Group. The international stroke trial (IST): a randomised trial of aspirin, subcutaneous heparin, both or neither among 19 435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-81.
57. CAST (Chinese Acute Stroke Trial) Collaborative Group. Randomised placebo controlled trial of early aspirin use in 20 000 patients with acute stroke. Lancet 1997; 349: 1641-19.
58. Pathansali R, Bath PMW. IST and CAST: some answers but more questions [Commentary]. J Hum Hypertens 1998; 12: 73-74.
59. ISIS-2 (Second International Trial of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988: ii: 349-60.
60. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians health study. N Engl J Med 1989; 321: 129-35.
61. Peto R, Gray R, Collins R et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313-16.
62. Hansson L, Zanchetti A, Carruthers SG et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
63. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular events by prolonged antiplatelet therapy. BMJ 1988; 296: 320-31.
64. Kristensen SD, Bath PMW, Martin JF. Differences in bleeding time, aspirin sensitivity and adrenaline between acute myocardial infarction and unstable angina. Cardiovasc Res 1990; 24: 19-23.
65. Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study 2. Dipyridamole and aspirin in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
66. CAPRIE Steering Committee. A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRlE). Lancet 1996; 348: 1329-39.
67. Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GPHb/IIIa antagonists. Thromb Haemost 1995; 74(1): 302-308.
68. Topol EJ, Califf RM, Weisman HF et al. Randomised trial of coronary intervention with antibody against platelet GPHb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC investigators. Lancet 1994; 343: 881-86.
69. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke prevention in atrial fibrillation study, final results. Circulation 1991; 84: 527-39.
70. Nyrop M, Zweifler AJ. Platelet aggregation in hypertension and the effects of antihypertensive treatment [Editorial Review]. J Hypertens 1988; 6: 263-69.
71. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than lower cholesterol [Viewpoint]. Lancet 1996; 348: 1079-82.
72. Mayer J, Eller T, Bracur P et al. Effects of long term treatment with lovastatin on the clotting system and blood platelets. Ann Haematol 1992; 64: 196-201.